Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
Neurology
    October 2025
  1. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
    Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2025;105:e213977.
    >> Share

  2. O'NEILL KA, Charvet L, Waltz M, George A, et al
    Cognitive Function in People With Pediatric Multiple Sclerosis Over 2 Years.
    Neurology. 2025;105:e214142.
    >> Share

  3. OLIVIERI E, Muller J, Toosy AT
    Predicting Disability Using PIRA in Multiple Sclerosis: Is It as Straightforward as It Appears?
    Neurology. 2025;105:e214206.
    >> Share

  4. PORTACCIO E, Amato MP
    Moving Closer to the Prevention of Cognitive Disability in People With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;105:e214244.
    >> Share

  5. SERRAO C, Rodrigues R, Guerreiro CL, Oliveira J, et al
    Pearls & Oy-sters: Adult-Onset Coats Plus: A Case of Leukoencephalopathy With Calcifications, a Tumefactive Brain Lesion, and a Presumed Autoimmune Disease.
    Neurology. 2025;105:e214124.
    >> Share

  6. NAUTIYAL K, Roy Chowdhury S, Meena R, Reddy N, et al
    Child Neurology: Parainfectious Anti-NMDAR Encephalitis With Anti-MOG and Anti-AQP4 Seropositivity in an Infant.
    Neurology. 2025;105:e214125.
    >> Share

    September 2025
  7. THAKOLWIBOON S, Redenbaugh V, Chen B, Hewitt S, et al
    Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Neurology. 2025;105:e213903.
    >> Share

  8. CORTESE R, Sforazzini F, Gentile G, de Mauro A, et al
    Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated Disease.
    Neurology. 2025;105:e214075.
    >> Share

  9. RENNER B, Verter ED, Absinta M, Daboul L, et al
    Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic.
    Neurology. 2025;105:e213912.
    >> Share

  10. CHARD DT
    Diagnosing Multiple Sclerosis: An Imperfect but Evolving Process.
    Neurology. 2025;105:e214057.
    >> Share

  11. MAREFI A, Grasso EA, Canna SW, Behrens EM, et al
    Clinical Reasoning: A 9-Year-Old Girl With CNS Immune Dysregulation.
    Neurology. 2025;105:e213999.
    >> Share

    August 2025
  12. HACOHEN Y, Ciccarelli O, Kunchok AC
    Diagnostic Criteria for Autoimmune Encephalitis in Children: Challenges and Need for Clinical Expertise.
    Neurology. 2025;105:e213946.
    >> Share

  13. SIEGLER JE, Galetta SL
    Editors' Note: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2025;105:e213926.
    >> Share

  14. MENON D, Bril V, Barnett-Tapia C
    Author Response: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2025;105:e210073.
    >> Share

  15. XU L, Zhou B, Xu Y
    Reader Response: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2025;105:e210041.
    >> Share

  16. GAVOILLE A, Leray E, Marignier R, Rollot F, et al
    Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
    Neurology. 2025;105:e213907.
    >> Share

  17. BSTEH G, Hegen H
    Bridging the Sex Gap: Confronting Therapeutic Inertia in Women With Multiple Sclerosis.
    Neurology. 2025;105:e214073.
    >> Share

  18. AL-ARAJI S, Moccia M, Jha A, Zhang L, et al
    Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;105:e213967.
    >> Share

  19. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;105:e213909.
    >> Share

  20. CORTESE M, Peng X, Edan G, Freedman MS, et al
    Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
    Neurology. 2025;105:e213905.
    >> Share

  21. ROBIN C, Rollot F, Lefort M, Casey R, et al
    Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
    Neurology. 2025;105:e213744.
    >> Share

  22. BOURDETTE D, Wooliscroft L
    Late-Onset Multiple Sclerosis: Is Disease-Modifying Therapy Indicated?
    Neurology. 2025;105:e213971.
    >> Share

  23. CABRAL A, Lopes da Mota C, Rodrigues Casanova S, Martins de Campos A, et al
    Pearls & Oy-Sters: Pan-Neurofascin Nodo-Paranodopathy Presenting as Fulminant Guillain-Barre Syndrome.
    Neurology. 2025;105:e213848.
    >> Share

    July 2025
  24. WU L, Jiang W, Du R, Liu Y, et al
    Clinical Reasoning: Acute and Progressive Cognitive Decline in a 38-Year-Old Man.
    Neurology. 2025;105:e213871.
    >> Share

  25. PETERSSON M, Jons D, Feresiadou A, Ilinca A, et al
    Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG Study.
    Neurology. 2025;105:e213771.
    >> Share

  26. ZHOU J, Nilius S, Pilipczuk O, Scowcroft A, et al
    Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States: A Cohort Study Using Health Care Claims Databases.
    Neurology. 2025;105:e213736.
    >> Share

  27. JIA A, Price TR, Rosner J, Broderick C, et al
    Journal Club: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e213663.
    >> Share

    June 2025
  28. GOYNE C, Fair AE, Yilmaz D, Race J, et al
    Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;104:e213673.
    >> Share

  29. JUL JARBAEK NIELSEN J, Levison L, Andersen H
    Mortality in Myasthenia Gravis in Denmark From 1985 to 2020: A Population-Based Cohort Study.
    Neurology. 2025;104:e213745.
    >> Share

  30. YEH EA
    Accelerated Aging in Children With Multiple Sclerosis: Can We Stop the Clock?
    Neurology. 2025;104:e213840.
    >> Share

  31. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
    Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
    Neurology. 2025;104:e213650.
    >> Share

    May 2025
  32. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EMM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2025;104:e213618.
    >> Share

  33. LANGER-GOULD A, Li BH, Smith JB, Kanter MH, et al
    Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level.
    Neurology. 2025;104:e213607.
    >> Share

  34. KAPPOS L, Yiu S, Dahlke F, Coetzee T, et al
    Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.
    Neurology. 2025;104:e213558.
    >> Share

  35. FOX RJ, Rudick RA
    A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability Worsening.
    Neurology. 2025;104:e213672.
    >> Share

  36. DINOTO A, Cacciaguerra L, Vorasoot N, Redenbaugh V, et al
    Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Neurology. 2025;104:e213557.
    >> Share

  37. VU AP, Kapadia RK, Roberts JI
    Pearls & Oy-sters: Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Presenting as Encephalomyelitis With Leptomeningeal Enhancement.
    Neurology. 2025;104:e213662.
    >> Share

  38. MARRIE RA, Sharma M, Cutter GR, Fox RJ, et al
    Perspectives of People With Multiple Sclerosis Regarding Data Linkage and Sharing.
    Neurology. 2025;104:e213587.
    >> Share

  39. CHAGGAR G, Waldner D, Scozzafava J, Harrison R, et al
    Teaching NeuroImage: Severe Enterovirus Encephalitis as a Complication of Ocrelizumab Treatment for Multiple Sclerosis.
    Neurology. 2025;104:e213585.
    >> Share

  40. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;104:e213574.
    >> Share

  41. ZARA P, Chessa P, Deiana GA, Morette AM, et al
    Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice.
    Neurology. 2025;104:e213498.
    >> Share

  42. GUINEBRETIERE O, Pierret C, Calonge Q, Januel E, et al
    Updated Multiple Sclerosis Incidence in France, 2011-2021.
    Neurology. 2025;104:e213586.
    >> Share

    April 2025
  43. ZELIKOVICH AS, Zamorska B, Michaelson NM
    Patient Perspectives: Patient as Teacher: The Impact of Listening to a Patient With Stiff-Person Syndrome on Her Disease Course.
    Neurology. 2025;104:e213433.
    >> Share

  44. NAKAJIMA A, Hokari M, Yanagimura F, Saji E, et al
    Long-Term Clinical Landscapes of Spinal Hypertrophic Pachymeningitis With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Neurology. 2025;104:e213420.
    >> Share

  45. AL-SALAHAT A, Abdul Jabbar AB, Sharma R, Chen YT, et al
    Demographic and Geographic Trends in Myasthenia Gravis-Related Mortality in the United States, 1999-2022.
    Neurology. 2025;104:e213505.
    >> Share

  46. ABBOUD H, Clardy SL, Dubey D, Wickel J, et al
    The Clinical Trial Landscape in Autoimmune Encephalitis: Challenges and Opportunities.
    Neurology. 2025;104:e213487.
    >> Share

  47. BROWNLEE WJ, Foster MA, Pontillo G, Davagnanam I, et al
    Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis.
    Neurology. 2025;104:e210274.
    >> Share

  48. GANESH A, Galetta SL
    Editors' Note: Domestic Violence and Abuse in People Living With Multiple Sclerosis.
    Neurology. 2025;104:e213407.
    >> Share

  49. VIDAL-JORDANA A, Ontaneda D
    To Kill Time: A Bold Step Toward Simplifying Multiple Sclerosis Diagnosis.
    Neurology. 2025;104:e213416.
    >> Share

  50. MAHAJAN KR, Herman D, Zheng Y, Androjna C, et al
    Neurodegeneration and Demyelination in the Multiple Sclerosis Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives.
    Neurology. 2025;104:e210259.
    >> Share

  51. MAVRIDIS A, Viktorisson A, Eliasson B, von Euler M, et al
    Risk of Ischemic and Hemorrhagic Stroke in Individuals With Type 1 and Type 2 Diabetes: A Nationwide Cohort Study in Sweden.
    Neurology. 2025;104:e213480.
    >> Share

  52. MCAREE M, Frontera JA
    Clinical Reasoning: A 56-Year-Old Woman With New-Onset Hoarseness and Dysphagia.
    Neurology. 2025;104:e213363.
    >> Share

    March 2025
  53. GOH WGW, Ng IKS, Tan MKX, Fong CYK, et al
    Clinical Reasoning: A 26-Year-Old Woman With Headache and Eosinophilia.
    Neurology. 2025;104:e213434.
    >> Share

  54. MAILLART E, Dubessy AL, Shor N, Piljan M, et al
    Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2025;104:e213399.
    >> Share

  55. GOMEZ-FIGUEROA E, Moreno-Bernardino CJ, De Alba-Sanchez AM, Guerrero-Udave N, et al
    The Burden of Multiple Sclerosis in Mexico.
    Neurology. 2025;104:e213343.
    >> Share

    February 2025
  56. TRANFA M, Petracca M, Moccia M, Scaravilli A, et al
    Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their Clinical Correlates in Multiple Sclerosis.
    Neurology. 2025;104:e213349.
    >> Share

  57. MARRIE RA, Bolton J, Ling YV, Bernstein C, et al
    Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada.
    Neurology. 2025;104:e210170.
    >> Share

  58. DERSCH RS, Fingerle V, Berns J, Rauer S, et al
    Pearls & Oy-sters: Recurrent Lyme Neuroborreliosis With Seroreversion in a Patient With Multiple Sclerosis on a B-Cell Depleting Therapy.
    Neurology. 2025;104:e213330.
    >> Share

  59. ROSS LA
    Peripartum Mental Illness in Mothers With Multiple Sclerosis Merits Neurologists' Attention.
    Neurology. 2025;104:e213366.
    >> Share

  60. CERQUEIRA JJ, Berthele A, Cree BAC, Filippi M, et al
    Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
    Neurology. 2025;104:e210142.
    >> Share

  61. COBO-CALVO A, Carbonell-Mirabent P, Tur C, Otero-Romero S, et al
    Age-Related Disability Outcomes After a First Demyelinating Event.
    Neurology. 2025;104:e210305.
    >> Share

  62. KRYSKO KM, Waltz M, Chitnis T, Weinstock-Guttman B, et al
    Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis.
    Neurology. 2025;104:e210213.
    >> Share

  63. ROCCA MA, Preziosa P, Filippi M
    Age Matters in Multiple Sclerosis: Novel Insights Into Disease Progression From Clinical Onset.
    Neurology. 2025;104:e213396.
    >> Share

  64. BRENTON JN
    Menarche and Relapses in Multiple Sclerosis: Associations Between a Physiologic Developmental Milestone and Disease Activity.
    Neurology. 2025;104:e213321.
    >> Share

  65. BALCOM EF, Mccombe JA, Kate MP, Vu K, et al
    Inequities in the Use of Disease-Modifying Therapy Among Adults Living With Multiple Sclerosis in Urban and Rural Areas in Alberta, Canada.
    Neurology. 2025;104:e210251.
    >> Share

  66. CARVAJAL R, Guananga-Alvarez D, Tur C, Esperalba J, et al
    Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.
    Neurology. 2025;104:e210281.
    >> Share

  67. AMEZCUA L, Cardenas-Iniguez C, Orlando C, Martinez A, et al
    Person-Centered Social Determinants and Neighborhood-Level Deprivation Associated With Disability in Hispanic People With Multiple Sclerosis.
    Neurology. 2025;104:e213332.
    >> Share


  68. Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis.
    Neurology. 2025;104:e210299.
    >> Share


  69. Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
    Neurology. 2025;104:e210298.
    >> Share

    January 2025
  70. TSAI CC, Chen J, Pikula A, Johnson EL, et al
    Opinion & Special Articles: Beyond Pronouns-Educating Trainees on the Impact of Language on Gender Inclusivity in Neurologic Practice.
    Neurology. 2025;104:e210289.
    >> Share

  71. SILVERMAN HE, Bostrom A, Nylander AN, Akula A, et al
    Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
    Neurology. 2025;104:e210228.
    >> Share

  72. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
    Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.
    Neurology. 2025;104:e210149.
    >> Share

  73. CARVALHO IV, Gomes F, Almendra L, Geraldo A, et al
    Reversible Unilateral Tongue Border Atrophy Associated With Anti-Acetylcholine Receptor Antibody-Positive Myasthenia Gravis.
    Neurology. 2025;104:e210288.
    >> Share

  74. CAGOL A, Montobbio N
    Reassuring Insights Into the Effect of COVID-19 on Symptoms and Disability in People With Multiple Sclerosis: Weathering the Storm.
    Neurology. 2025;104:e210272.
    >> Share

  75. CRUCIANI A, Toosy AT
    Progression Independent of Relapse Activity in Multiple Sclerosis: More, or Less, Than Meets the Eye?
    Neurology. 2025;104:e210296.
    >> Share

  76. STRIJBIS EMM, Mostert J, Comtois J, Salter A, et al
    Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;104:e210153.
    >> Share

  77. WONG SH, Abuzaitoun R, Cornblath WT, Eggenberger ER, et al
    Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire.
    Neurology. 2025;104:e210150.
    >> Share

  78. MONGAY-OCHOA N, Pareto D, Alberich M, Carbonell-Mirabent P, et al
    Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis.
    Neurology. 2025;104:e210136.
    >> Share

  79. CHEN B, Francis A, Cooper SA, Dobson R, et al
    Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2025;104:e210137.
    >> Share

  80. JUL JARBAEK NIELSEN J, Levison L, Andersen H
    Changes in Myasthenia Gravis Incidence in Denmark From 1985 to 2021: A Nationwide Population-Based Study.
    Neurology. 2025;104:e210139.
    >> Share

    December 2024
  81. RIMKUS CM, Nucci MP, Avolio IB, Apostolos-Pereira SL, et al
    Atrophy Patterns in Patients With Multiple Sclerosis With Cognitive Impairment, Fatigue, and Mood Disorders.
    Neurology. 2024;103:e210080.
    >> Share

  82. BRENNER J, Ruhe CJ, Kulderij I, Bastiaansen AEM, et al
    Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis.
    Neurology. 2024;103:e210109.
    >> Share

  83. SIRIRATNAM P, Huda S, Van Der Walt A, Sanfilippo PG, et al
    Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
    Neurology. 2024;103:e209940.
    >> Share

  84. ROSS R, O'Neill KA, Betensky RA, Billiet T, et al
    Association of Social Determinants of Health With Brain MRI Outcomes in Individuals With Pediatric Onset Multiple Sclerosis.
    Neurology. 2024;103:e210140.
    >> Share

  85. HARTUNG HP, Benedict RHB, Berger T, Bermel RA, et al
    Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
    Neurology. 2024;103:e210049.
    >> Share

  86. CRANE PD, Sillau S, Dreher R, Fix R, et al
    Population-Based Study of the Epidemiology of Stiff Person Syndrome in a Large Colorado-Based Health System.
    Neurology. 2024;103:e210078.
    >> Share

  87. KLEIN CJ, Triplett JD, Murray DL, Gorsh AP, et al
    Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.
    Neurology. 2024;103:e210000.
    >> Share

  88. QUINN CM, Rajarajan P, Gill AJ, Kopinsky H, et al
    Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
    Neurology. 2024;103:e210003.
    >> Share

  89. WILSON E, Meeks HD, Barney BJ, Waltz M, et al
    Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States.
    Neurology. 2024;103:e209991.
    >> Share

    November 2024
  90. REEVES JA, Bartnik A, Jakimovski D, Mohebbi M, et al
    Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.
    Neurology. 2024;103:e210004.
    >> Share

  91. WATANABE M, Isobe N, Niino M, Nakashima I, et al
    Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.
    Neurology. 2024;103:e209992.
    >> Share

  92. SANTILLI AR, Ni O, Milone M, Selcen D, et al
    Immune-Mediated Megaconial Myopathy: A Novel Subtype of Autoimmune Myopathy.
    Neurology. 2024;103:e210001.
    >> Share

  93. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
    Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
    Neurology. 2024;103:e210029.
    >> Share

  94. SHARMA R, Bellacicco NJ, Husar WG, Park JH, et al
    Pearls & Oy-sters: Breaking Bad CIDP: Recognition of Anti-NF155 Autoimmune Nodopathy in Refractory CIDP.
    Neurology. 2024;103:e209848.
    >> Share

  95. MICHAELSON NM, Klawiter EC, Singhal T
    Journal Club: PET Imaging in Multiple Sclerosis and Its Prognostic Implications.
    Neurology. 2024;103:e210047.
    >> Share

  96. PONTILLO G, Prados F, Colman J, Kanber B, et al
    Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
    Neurology. 2024;103:e209976.
    >> Share

  97. BRUCKMAN D, Lee I, Schold JD, Claytor BR, et al
    Epidemiologic Study of Myasthenia Gravis in the Elderly US Population: A Longitudinal Analysis of the Medicare Claims Database, 2006-2019.
    Neurology. 2024;103:e210005.
    >> Share


  98. Predicting Outcome in Guillain-Barre Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
    Neurology. 2024;103:e209968.
    >> Share

  99. BROEDERS TAA, van Dam M, Pontillo G, Rauh V, et al
    Energy Associated With Dynamic Network Changes in Patients With Multiple Sclerosis and Cognitive Impairment.
    Neurology. 2024;103:e209952.
    >> Share

  100. PIERRET C, Mulliez A, Le Bihan-Benjamin C, Moisset X, et al
    Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2024;103:e209885.
    >> Share

  101. GUPTA J, Choudhary R, Gupta A, Sharma P, et al
    Child Neurology: Acute Necrotizing Encephalopathy of Childhood Associated With Dengue: Good Neurologic Outcome Despite a Fulminant Presentation.
    Neurology. 2024;103:e209954.
    >> Share

  102. SIEGLER JE, Galetta SL
    Editors' Note: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209934.
    >> Share

  103. MOEHLMAN M
    Author Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209565.
    >> Share

  104. YANG Y, Li J, Tang Y
    Reader Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209545.
    >> Share

  105. MARIGNIER R, Kunchok A
    Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines.
    Neurology. 2024;103:e209970.
    >> Share

  106. RINGELSTEIN M, Asseyer S, Lindenblatt G, Fischer K, et al
    Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
    Neurology. 2024;103:e209888.
    >> Share

    October 2024
  107. SILVERMAN A, Sasaki M, Espindola Lima JE, Cheronis C, et al
    Child Neurology: Remarkable Recovery From Severe Acute Necrotizing Encephalopathy.
    Neurology. 2024;103:e209877.
    >> Share

  108. XU TT, Kaplan TM, Chen JJ
    Teaching NeuroImages: Cilioretinal Artery Occlusion Secondary to Antiphospholipid Syndrome.
    Neurology. 2024;103:e209901.
    >> Share

  109. SIEGLER JE 3RD, Galetta S
    Editors' Note: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209893.
    >> Share

  110. GROBOIS L, You M, Etienne M
    Reader Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209508.
    >> Share

  111. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Author Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209515.
    >> Share

  112. HAY M, Rollot F, Casey R, Kerbrat A, et al
    Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
    Neurology. 2024;103:e209886.
    >> Share

  113. YOKOTE H, Mori K, Nakamichi K, Matsuda T, et al
    Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML.
    Neurology. 2024;103:e209874.
    >> Share

  114. ROBERTS JI, Ng D, Kapadia R
    Pearls & Oy-sters: Tumour-Like Mass Lesion Secondary to Primary CNS Vasculitis.
    Neurology. 2024;103:e209819.
    >> Share


  115. Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results From Structured Interviews (P1-6.015).
    Neurology. 2024;103:e209905.
    >> Share


  116. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;103:e209461.
    >> Share

  117. LOONSTRA FC, Alvarez Sirvent D, Tesi N, Holstege H, et al
    Association of Polygenic Risk Score With Lifetime Risk of Developing Multiple Sclerosis in a Population-Based Birth-Year Cohort.
    Neurology. 2024;103:e209663.
    >> Share

  118. BLACKOWICZ M, James J, McNeil-Posey K, Schwartz T, et al
    Socioeconomic Factors Associated with >/=2-year Delayed Diagnosis of Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States.
    Neurology. 2024;103.
    >> Share

  119. MANGIORIS G, Orozco E, Dubey D, Flanagan E, et al
    Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis: A Retrospective Study.
    Neurology. 2024;103.
    >> Share

  120. VENKATARAMAN I, Ott A, Miske R, Scharf M, et al
    Performance Assessment of the New EUROLINE Neurologic Syndrome 15 Ag (IgG) for the Determination of Autoantibodies Associated with Neurological Disorders.
    Neurology. 2024;103.
    >> Share

    September 2024
  121. ROHM Z, Mobley B, Pawate S
    Teaching NeuroImage: Immunoglobulin G4-Related Hypophysitis.
    Neurology. 2024;103:e209809.
    >> Share

  122. ROVIRA A, Pareto D
    chi-Separation as a Novel MRI Biomarker for Assessing Disease Progression in Multiple Sclerosis: Divide and Conquer.
    Neurology. 2024;103:e209735.
    >> Share

  123. MULLER J, Lu PJ, Cagol A, Ruberte E, et al
    Quantifying Remyelination Using chi-Separation in White Matter and Cortical Multiple Sclerosis Lesions.
    Neurology. 2024;103:e209604.
    >> Share

  124. BOURDETTE D
    Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment.
    Neurology. 2024;103:e209835.
    >> Share

  125. BSTEH G, Aicher ML, Walde JF, Krajnc N, et al
    Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
    Neurology. 2024;103:e209752.
    >> Share

  126. BANKS SA, Brinjikji W, Giannini C, Syc-Mazurek SB, et al
    Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions.
    Neurology. 2024;103:e209739.
    >> Share

  127. ZARA P, Solla P, Damato V, Sechi E, et al
    Teaching Video NeuroImage: The "Chameleon Eyes Sign" in Myasthenia Gravis.
    Neurology. 2024;103:e209756.
    >> Share

  128. SHIMIZU A, Noguchi-Shinohara M, Komatsu J, Ono K, et al
    Multifocal Intracranial Rosai-Dorfman Disease Mimicking Immunoglobulin G4-Related Pachymeningitis.
    Neurology. 2024;103:e209741.
    >> Share

  129. ABBOUD H, Farez MF
    The Risk of Multiple Sclerosis Relapse After Vaccination: Can a Population-Based Study of Mass Vaccination End the Longstanding Debate?
    Neurology. 2024;103:e209761.
    >> Share

  130. MOISSET X, Leray E, Chenaf C, Taithe F, et al
    Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
    Neurology. 2024;103:e209662.
    >> Share

    August 2024
  131. KARALIUS M, Mohan S, Paredes D, Rasool N, et al
    Pearls & Oy-sters: Optic Neuritis as First Demyelinating Event During Pregnancy in 2 Young Hispanic Women: MS vs MOGAD.
    Neurology. 2024;103:e209706.
    >> Share

  132. PASCUAL-GONI E, Caballero-Avila M, Querol L
    Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
    Neurology. 2024;103:e209725.
    >> Share

  133. MENON D, Alharbi M, Katzberg HD, Bril V, et al
    Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2024;103:e209722.
    >> Share

  134. TAGA A, Wali A, Eberhart CG, Green KE, et al
    Teaching NeuroImage: Giant Cell Arteritis With Optic Perineuritis.
    Neurology. 2024;103:e209707.
    >> Share

  135. WANG W
    Reader Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;103:e209441.
    >> Share

  136. WU J, Guo K, Liu J
    Author Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;103:e209463.
    >> Share

  137. LEWIS A, Galetta SL
    Editors' Note: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;103:e209736.
    >> Share


  138. Characterization Profiles of ANCA-associated Vasculitis With Neurological Manifestations (P7-14.007).
    Neurology. 2024;103:e209640.
    >> Share


  139. Artificial Intelligence-Based Ocular Motor Biomarkers for Myasthenia Gravis Diagnosis (P10-11.016).
    Neurology. 2024;103:e209639.
    >> Share

  140. MAYCOCK TJ, Rossor T, Vanegas M, Gringras P, et al
    Child Neurology: Common Occurrence of Narcolepsy Type 1 and Myasthenia Gravis.
    Neurology. 2024;103:e209598.
    >> Share

  141. SASTRE-GARRIGA J, Vidal-Jordana A, Toosy AT, Enzinger C, et al
    Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.
    Neurology. 2024;103:e209677.
    >> Share

  142. WILLIAMS MJ, Amezcua L, Cohan SL, Cohen JA, et al
    Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Neurology. 2024;103:e209610.
    >> Share

    July 2024
  143. PFEUFFER S, Wolff S, Aslan D, Rolfes L, et al
    Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
    Neurology. 2024;103:e209574.
    >> Share

  144. GRANGEON L, Boulouis G, Capron J, Bala F, et al
    Cerebral Amyloid Angiopathy-Related Inflammation and Biopsy-Positive Primary Angiitis of the CNS: A Comparative Study.
    Neurology. 2024;103:e209548.
    >> Share

  145. GAVAZZI F, Vaia Y, Woidill S, Formanowski B, et al
    Nonverbal Cognitive Skills in Children With Aicardi Goutieres Syndrome.
    Neurology. 2024;103:e209541.
    >> Share

  146. CICCARELLI O, Barkhof F, Calabrese M, De Stefano N, et al
    Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
    Neurology. 2024;103:e209444.
    >> Share

  147. MADSEN MA, Povazan M, Wiggermann V, Lundell H, et al
    Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis.
    Neurology. 2024;103:e209543.
    >> Share

    June 2024
  148. KAMINSKI HJ, Kusner LL, Cutter GR, Le Panse R, et al
    Does Surgical Removal of the Thymus Have Deleterious Consequences?
    Neurology. 2024;102:e209482.
    >> Share

  149. PALLADINO R, Monasta L
    Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
    Neurology. 2024;102:e209521.
    >> Share

  150. ZHANG C, Liu W, Wang L, Wang F, et al
    Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
    Neurology. 2024;102:e209351.
    >> Share

    May 2024
  151. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
    Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Neurology. 2024;102:e209303.
    >> Share

  152. SILBERMANN E, Spain RI
    Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
    Neurology. 2024;102:e209456.
    >> Share

  153. FOX RJ, Cree BAC, de Seze J, Gold R, et al
    Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209357.
    >> Share

  154. VALKO Y, Wirth MA, Fierz FC, Schesny MK, et al
    Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
    Neurology. 2024;102:e209395.
    >> Share

  155. LIAO J, Lu Y, Lu Y, Huang Y, et al
    Cardiopulmonary Coupling Spectrogram as an Ambulatory Method for Assessing Sleep Disorders in Patients With Autoimmune Encephalitis.
    Neurology. 2024;102:e209302.
    >> Share

  156. MICHAELSON NM
    Right Brain: The Unraveling.
    Neurology. 2024;102:e209492.
    >> Share

  157. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
    Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
    Neurology. 2024;102:e209350.
    >> Share

  158. TANG A, Yoshida K, Lahey H, Wilcox DR, et al
    Herpes Simplex Virus Encephalitis in Patients With Autoimmune Conditions or Exposure to Immunomodulatory Medications.
    Neurology. 2024;102:e209297.
    >> Share

    April 2024
  159. ZOUVELOU V, Petrou EM, Strataki E, Vasileiou V, et al
    Pearls & Oy-sters: Thyroid-Associated Ophthalmopathy and Transient Neuromuscular Junction Disorder Due to Graves Disease.
    Neurology. 2024;102:e209282.
    >> Share

  160. DEMORTIERE S, Joubert B, Benaiteau M, Hilezian F, et al
    Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis.
    Neurology. 2024;102:e209284.
    >> Share

  161. MOEHLMAN M, Kornbluh AB
    Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;102:e209259.
    >> Share


  162. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
    Neurology. 2024;102:e209214.
    >> Share

  163. OYAMA M, Holzer MT, Ohnuki Y, Saito Y, et al
    Pathologic Features of Anti-Ku Myositis.
    Neurology. 2024;102:e209268.
    >> Share

  164. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
    MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
    Neurology. 2024;102:e209199.
    >> Share

  165. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    >> Share

  166. TOGNI CL, Frontzek K, Schubring-Giese M, Imbach LL, et al
    Posttransplant Anti-GABA(A) Receptor Antibody-Associated Autoimmune Encephalitis.
    Neurology. 2024;102:e209245.
    >> Share

  167. THAKOLWIBOON S, Dubey D
    Redefining Patient Evaluation in Anti-IgLON5 Disease: Anti-IgLON5 Disease Composite Score.
    Neurology. 2024;102:e209213.
    >> Share

  168. GAIG C, Gruter T, Heidbreder A, Sabater L, et al
    Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease.
    Neurology. 2024;102:e208101.
    >> Share

  169. KOTHAPALLI NP, Chompoopong P, McKeon A, Dubey D, et al
    Teaching Video NeuroImage: Adaptor-Related Protein-Complex-3 Subunit beta-2 Immunoglobulin-G-Associated Autoimmune Ataxia.
    Neurology. 2024;102:e209257.
    >> Share

  170. AGYEI P, Chen M, Guo Y, Perez CA, et al
    Pearls & Oy-sters: KLHL11 IgG Paraneoplastic-Associated Hearing Loss and Rhombencephalitis in a Woman With Metastatic Mullerian Tumor.
    Neurology. 2024;102:e209187.
    >> Share

  171. KUHLMANN G, Cloud B
    Characterization of the Earliest Adopters of Subcutaneous FcRn Blockers for gMG (P4-14.013).
    Neurology. 2024;102.
    >> Share

  172. YU Y, Kushlaf H
    Multiple Sclerosis in a Patient with Friedreich's Ataxia (P4-6.016).
    Neurology. 2024;102.
    >> Share

  173. MASCANFRONI I, Manasson J, Pellerin A, Sanmarco L, et al
    Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases (P4-14.018).
    Neurology. 2024;102.
    >> Share

  174. WATANABE F, Fedorko J, Imitola J
    Dimethyl Fumarate Enhances Neural Stem Cell (NSC) Self-renewal and Neuroprotection in a Human Cellular Model of Multiple Sclerosis Inflammation-induced Neurodegeneration (P8-6.014).
    Neurology. 2024;102.
    >> Share

  175. OHRN S, Patel R, Ali A, Bauerschmidt A, et al
    Autonomic Dysfunction in Autoimmune Encephalitis: A Review of the Literature (P6-14.004).
    Neurology. 2024;102.
    >> Share

  176. ZAJNER C, Patil N, McInnis R, Van Uum S, et al
    Patterns of Extraocular Muscle Enlargement in Graves' Disease and Acromegaly (P7-10.005).
    Neurology. 2024;102.
    >> Share

  177. ROBERTS K, Cohn B, Sista SR
    Acetylcholine Binding Receptor Positivity from Passive Antibody Transfer in a Case of Progressive Muscular Atrophy (P11-11.009).
    Neurology. 2024;102.
    >> Share

  178. WEBER A, Rose J, DeWitt L
    NMOSD: Previously Seropositive Patient Presents with Seronegative Brainstem Attack (P11-14.017).
    Neurology. 2024;102.
    >> Share

  179. LOBAINA M, Valaparla VL, Shanina E
    Vogt-Koyanagi-Harada Disease an Autoimmune Comorbidity of Multiple Sclerosis, Not Just a Mimicker (P3-14.014).
    Neurology. 2024;102.
    >> Share

  180. HABIB AA, Kaminski HJ, Grosskreutz J, Mantegazza R, et al
    Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001).
    Neurology. 2024;102.
    >> Share

  181. KARAYI G, Quinones-Herrero N, Martin J, Chaudhry S, et al
    A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis (S31.010).
    Neurology. 2024;102.
    >> Share

  182. ROSE M, Hsu S, Balan A, Anderson A, et al
    Risk Factors for Peripartum Mood Disorders in Women with MS: A Prospective Study (P4-6.014).
    Neurology. 2024;102.
    >> Share

  183. JAFFRY K, Karpenos S, Lin J, Matos J, et al
    Climate Change Associated with Declining Clinical Outcomes in Myasthenia Gravis for US States with the Greatest Temperature Increase (P4-14.004).
    Neurology. 2024;102.
    >> Share

  184. MAKAROVA A, Raju S, Ciotti J
    Parainfectious Hemorrhagic Longitudinally-extensive Transverse Myelitis Secondary to COVID-19 (P1-13.010).
    Neurology. 2024;102.
    >> Share

  185. WOODSON S, Gettings E, Guo CY, Klineova S, et al
    Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005).
    Neurology. 2024;102.
    >> Share

  186. VARNET M, Kayani S, Wang C
    Diagnostic Journey and Therapeutic Intervention of a Type-1 Interferonopathy in a Newborn (P6-8.002).
    Neurology. 2024;102.
    >> Share

  187. MIKAMI T, Levy M
    Association of HLA-DRB1*15:01 Status with Transcriptomic Pattern of B cells in CSF in Multiple Sclerosis (P7-6.011).
    Neurology. 2024;102.
    >> Share

    March 2024
  188. YOUNG A, Johnston JL
    Pearls & Oy-sters: Ocular Myasthenia Gravis: Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator.
    Neurology. 2024;102:e209260.
    >> Share

  189. AOTSUKA Y, Misawa S, Suichi T, Shibuya K, et al
    Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients.
    Neurology. 2024;102:e209130.
    >> Share

  190. MARRIE RA, Salter A
    Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
    Neurology. 2024;102:e208099.
    >> Share

  191. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
    Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e208032.
    >> Share

  192. BOURDETTE D, Wooliscroft L
    The Challenges of Treating Late-Onset Multiple Sclerosis.
    Neurology. 2024;102:e209146.
    >> Share

  193. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;102:e208051.
    >> Share


  194. Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209252.
    >> Share

  195. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    >> Share

  196. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    >> Share

  197. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    >> Share

  198. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
    Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Neurology. 2024;102:e209147.
    >> Share

    February 2024
  199. MORGAN A, Li Y, Thompson NR, Milinovich A, et al
    Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.
    Neurology. 2024;102:e208019.
    >> Share

  200. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    >> Share

  201. BRANCH A, Nuaaman MM, Appleton CT, Connaughton DM, et al
    Teaching NeuroImage: Extensive Brainstem and Striatal Involvement in Neuropsychiatric Systemic Lupus Erythematosus.
    Neurology. 2024;102:e209153.
    >> Share

  202. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e207966.
    >> Share

  203. WU J, Guo K, Liu J
    Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;102:e208064.
    >> Share

  204. NG HS, Zhu F, Zhao Y, Yao S, et al
    Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
    Neurology. 2024;102:e208006.
    >> Share

  205. BELLUCCI M, Castellano C, Marinelli L, Garbarino L, et al
    Patient With Rigidity and Fasciculations.
    Neurology. 2024;102:e208110.
    >> Share

  206. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    >> Share

    January 2024
  207. GIBSON S, Mcgraw C
    Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
    Neurology. 2024;102:e208027.
    >> Share

  208. ANTOZZI C, Guptill J, Bril V, Gamez J, et al
    Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis.
    Neurology. 2024;102:e207937.
    >> Share

  209. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
    Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
    Neurology. 2024;102:e207916.
    >> Share

  210. HABIB AA, Sacks N, Cool C, Durgapal S, et al
    Hospitalizations and Mortality From Myasthenia Gravis.
    Neurology. 2024;102:e207863.
    >> Share

  211. LANGER-GOULD A, Sotirchos ES, Bourdette D
    Rituximab for Multiple Sclerosis.
    Neurology. 2024;102:e208063.
    >> Share

  212. GALETTA S, Brownlee W
    Assignment Completed.
    Neurology. 2024;102:e207913.
    >> Share

  213. TUR C, Rocca MA
    Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2024;102:e207936.
    >> Share

  214. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
    Neurology. 2024;102:e200805.
    >> Share

  215. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
    Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Neurology. 2024;102:e207768.
    >> Share

  216. VLAHOVIC L, McDonald J, Hinman J, Tomczak A, et al
    Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2024;102:e207965.
    >> Share

  217. ALKABIE S, Gray MT, Lau JC, Barra L, et al
    Teaching NeuroImage: Unilateral Primary Angiitis of the CNS.
    Neurology. 2024;102:e208018.
    >> Share

    December 2023
  218. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
    Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
    Neurology. 2023;101:e2483-e2496.
    >> Share

  219. SUNSHINE A, Mandle QJ, Cabal Herrera AM, Zapanta B, et al
    Pearls & Oy-sters: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child.
    Neurology. 2023;101:e2585-e2588.
    >> Share

  220. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
    Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
    Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
    >> Share

    November 2023
  221. LI X, Stitt D, Lanzino G, Giannini C, et al
    Teaching NeuroImage: Pachymeningitis and Aortitis as the Initial Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2023;101:979-980.
    >> Share

    October 2023
  222. SRIVASTAVA I, Van Haren K
    Immunotherapy in Autoimmune Encephalitis: So Many Options, So Few Guidelines.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000208026.
    >> Share

  223. BOURDETTE D, Silbermann E
    What Are the Risks of Guillain-Barre Syndrome Following SARS-CoV-2 Infection and COVID-19 Vaccination?
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207998.
    >> Share

  224. BISHARA H, Arbel A, Barnett-Griness O, Bloch S, et al
    Association Between Guillain-Barre Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207900.
    >> Share

  225. YANG JH, Liu EN, Nguyen L, Dunn-Pirio A, et al
    Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
    Neurology. 2023 Oct 12:10.1212/WNL.0000000000207746.
    >> Share

  226. GUASP M, Dalmau J
    Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
    Neurology. 2023;101:656-660.
    >> Share

  227. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
    Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
    >> Share

  228. LE VU S, Bertrand M, Botton J, Jabagi MJ, et al
    Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-controlled Case Series Study.
    Neurology. 2023 Oct 3:10.1212/WNL.0000000000207847.
    >> Share

    September 2023
  229. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
    Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Neurology. 2023;101:e1280-e1292.
    >> Share

  230. PALLADINO R, Strijbis EM
    How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
    >> Share

  231. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
    Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
    >> Share

  232. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
    Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
    >> Share

  233. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
    Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
    >> Share

  234. BUYUKKURT A, Harroud A
    The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
    >> Share

    July 2023
  235. QUINN C, Moulton K, Farwell M, Le W, et al
    Imaging With PET/CT of Diffuse CD8 T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207596.
    >> Share

  236. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
    >> Share

  237. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
    Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
    >> Share

    September 2022
  238. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
    Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
    >> Share

    August 2022
  239. BASTERRA PP, Nombela F, Iriarte P, Del Rincon CR, et al
    Proprioceptive Stimuli as a New Type of Trigger for Epilepsy in Stiff Person Syndrome.
    Neurology. 2022 Aug 31. pii: WNL.0000000000201196.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016